Evidence map›Paper›PMID 33957957›Full record

ArticleStem cell research & therapy2021

Mesenchymal stem and non-stem cell surgery, rescue, and regeneration in glaucomatous optic neuropathy.

Paolo Giuseppe Limoli, Celeste Limoli, Enzo Maria Vingolo, Federica Franzone, Marcella Nebbioso

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Stem cell research & therapy, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed, 2 pooled it
3.2field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 2 syntheses or guidelines pooled it, 20 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Review
  4. Article
  5. Article
  6. Review
  7. Review
  8. Review
  9. Article
  10. Review
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 3 institutions in 1 country.

Paolo Giuseppe LimoliLow Vision Research Centre of Milan, Piazza Sempione 3, 20145, Milan, Italy.
Celeste LimoliLow Vision Research Centre of Milan, Piazza Sempione 3, 20145, Milan, Italy.
Enzo Maria VingoloDepartment of Sense Organs, Faculty of Medicine and Odontology, Sapienza University of Rome, P.le A. Moro 5, 00185, Rome, Italy.
Federica FranzoneDepartment of Sense Organs, Faculty of Medicine and Odontology, Sapienza University of Rome, P.le A. Moro 5, 00185, Rome, Italy.
Marcella NebbiosoDepartment of Sense Organs, Faculty of Medicine and Odontology, Sapienza University of Rome, P.le A. Moro 5, 00185, Rome, Italy. marcella.nebbioso@uniroma1.it.ORCID 0000-0002-5512-0849
European School of Molecular Medicine · ITSapienza University of Rome · ITPoliclinico Umberto I · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundGlaucomatous optic neuropathy (GON) is an anatomofunctional impairment of the optic nerve triggered by glaucoma. Recently, growth factors (GFs) have been shown to produce retinal neuroenhancement. The suprachoroidal autograft of mesenchymal stem cells (MSCs) by the Limoli retinal restoration technique (LRRT) has proven to achieve retinal neuroenhancement by producing GF directly into the choroidal space. This retrospectively registered clinical study investigated the visual function changes in patients with GON treated with LRRT.

methodsTwenty-five patients (35 eyes) with GON in progressive disease conditions were included in the study. Each patient underwent a comprehensive ocular examination, including the analysis of best corrected visual acuity (BCVA) for far and near visus, sensitivity by Maia microperimetry, and the study of the spectral domain-optical coherence tomography (SD-OCT). The patients were divided into two groups: a control group, consisting of 21 eyes (average age 72.2 years, range 50-83), and an LRRT group, consisting of 14 eyes (average age 67.4, range 50-84).

resultsAfter 6 months, the BCVA, close-up visus, and microperimetric sensitivity significantly improved in the LRRT-treated group (p<0.05), whereas the mean increases were not statistically significant in controls (p>0.5).

conclusionsPatients with GON treated with LRRT showed a significant increase in visual performance (VP) both in BCVA and sensitivity and an improvement of residual close-up visus, in the comparison between the LRRT results and the control group. Further studies will be needed to establish the actual significance of the reported findings.

Indexed as

GlaucomaOptic Nerve DiseasesAgedAged, 80 and overHumansMiddle AgedOptic NerveRetinaTomography, Optical CoherenceAdipose-derived stem cellAutograftCell surgeryGlaucomaGlaucomatous optic neuropathyGrowth factor (GF)Limoli retinal restoration technique (LRRT)Mesenchymal stem cell (MSC)Platelet-rich plasmaStem cells

Identifiers

PMID33957957
PMCPMC8101217
OpenAlexW3157500078

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.